Prognostic value of the “dynamic” second revision of the international staging system (R2- ISS) in patients with multiple myeloma undergoing anti-CD38 antibody, carfilzomib, and dexamethasone therapy

Kikuchi, Taku; Tsukada, Nobuhiro; Kunisada, Kodai; Matsumoto, Chiaki; Nomura‐Yogo, Moe; Oda, Yuki; Sato, Kota; Takei, Tomomi; Ogura, Mizuki; Abe, Yu; Suzuki, Kenshi; Hosaya, Osamu; Ishida, Tadao

doi:10.21203/rs.3.rs-4113413/v1

Public

Prognostic value of the “dynamic” second revision of the international staging system (R2- ISS) in patients with multiple myeloma undergoing anti-CD38 antibody, carfilzomib, and dexamethasone therapy

Published in Research Square • Mar 21, 2024

Authors:

Taku Kikuchi

Nobuhiro Tsukada

Kodai Kunisada

Abstract

Abstract Recently, the second revision of the International Staging System (R2-ISS) has emerged as a prognostic tool for multiple myeloma (MM) and is known to be useful for prognostication at the time of diagnosis. Treatment outcomes for MM have significantly improved with the introduction of novel ...

Subject

Carfilzomib

Dexamethasone

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!